In the Claims:

1. - 14. (Cancelled).

15. (Currently Amended) A pharmaceutical composition containing a compound as defined in Formula I



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from ~~the group consisting of~~; hydrogen, halogen, C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} alkoxy, C_1-C_{10} alkenoxy, C_1-C_{10} alkynoxy, C_1-C_{10} alkylthio, C_1-C_{10} alkenylthio, C_1-C_{10} alkynylthio, C_6-C_{10} arylthio, C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C1-C_{10} alkylarylsulphoxide, C_6-C_{10} aryl, or C_5-C_{20} heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R_1 and R_2 may together form a C_3-C_{10} cycloalkyl group;

R_3 and R_4 are the same or different and independently selected from hydrogen, halogen, C_1-C_{20} alkyl, C_3-C_7 cycloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 alkoxy, C_1-C_4 alkenoxy, C_1-C_4 alkynoxy, C_1-C_4 alkylthio, C_1-C_4 alkenylthio, C_1-C_4 alkynylthio C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C_1-C_{10} alkylarylsulphoxide, C_6-C_{15} aryl, C_5-C_{20} heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R_5 is chosen from ~~the group consisting of;~~ nitro, cyano, -CH_2CN, -COMe, ~~acetic acid, halogen, sulphonic acid,~~ or -SO_2CH_3;~~, aldehyde, carboxylic acid or ester, phosphonic acid or ester;~~

R_6 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CN, CO_2H, CHF_2, CH_2F or CF_3;

Z is chosen from CR_7 or N;

R_7 is chosen from the group consisting of; H~~, halogen~~ or C_1-C_5 alkyl;

R_8 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CHF_2, CH_2F or CF_3;

X is ~~chosen from the group consisting of;~~ -NH-~~, -O-, -S-, -SO-, -SO2-, -Se-, -Te- or -S-S-~~

Y is chosen from ~~the group consisting of; hydrogen,~~ hydroxy~~, CH2OH, methoxy, NH_2, unbranched, branched or cyclic C_1-C_5 alkyl, unbranched, branched or cyclic -NH(C_1-C_8); unbranched, branched or cyclic N(C_1-C_8)$_2$, -NH(C_6aryl), -N(C_6aryl)$_2$,~~ or -NH(C_1-C_{10} heteroaryl)~~; and -N(C_5-C_{10} heteroaryl)$_2$, C_5-C_{10} heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;~~

~~Z is chosen from the group consisting of; C, N, or O;~~

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO_2H, CHO, NO_2, $-NH_2$, $-NH(C_1-C_4)$; $N(C_1-C_4)_2$, $-NH(C_6$ aryl), $-N(C_6$ aryl$)_2$, $-NH(C_5-C_{10}$ heteroaryl), and $-N(C_5-C_{10}$ heteroaryl$)_2$; or a pharmaceutically acceptable salt thereof.

16. - 17. (Cancelled).

18. (Currently Amended) A compound as defined by Formula I:



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from ~~the group consisting of;~~ hydrogen, halogen, C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} alkoxy, C_1-C_{10} alkenoxy, C_1-C_{10} alkynoxy, C_1-C_{10} alkylthio, C_1-C_{10} alkenylthio, C_1-C_{10} alkynylthio, C_6-C_{10} arylthio, C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10}

alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C1-C_{10} alkylarylsulphoxide, C_6-C_{10} aryl, or C_5-C_{20} heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R_1 and R_2 may together form a C_3-C_{10} cycloalkyl group;

R_3 and R_4 are the same or different and independently selected from hydrogen, halogen, C_1-C_{20} alkyl, C_3-C_7 cycloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 alkoxy, C_1-C_4 alkenoxy, C_1-C_4 alkynoxy, C_1-C_4 alkylthio, C_1-C_4 alkenylthio, C_1-C_4 alkynylthio C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C_1-C_{10} alkylarylsulphoxide, C_6-C_{15} aryl, C_5-C_{20} heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R_5 is chosen from ~~the group consisting of;~~ nitro, cyano, $-CH_2CN$, -COMe, or ~~acetic acid, halogen, sulphonic acid,~~ $-SO_2CH_3$~~;, aldehyde, carboxylic acid or ester, phosphonic acid or ester;~~

R_6 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CN, CO_2H, CHF_2, CH_2F or CF_3;

~~R_7 is chosen from the group consisting of; H, halogen or C_1-C_5 alkyl;~~

R_8 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CHF_2, CH_2F or CF_3;

X is ~~chosen from the group consisting of;~~ -NH-~~;, -O-, -S-, -SO-, $-SO_2$-, -Se-, -Te- or -S-S-~~

Y is chosen from ~~the group consisting of; hydrogen,~~ hydroxy, or ~~-CH2OH, methoxy, NH_2, unbranched, branched or cyclic C_1-C_5 alkyl, unbranched, branched or cyclic -NH(C_1-C_8); unbranched, branched or cyclic N(C_1-C_8)$_2$, -NH(C_6aryl), -N(C_6aryl)$_2$,~~ -NH(C_1-C_{10} heteroaryl)~~;~~;

~~and $-N(C_5-C_{10}$ heteroaryl)$_2$, C_5-C_{10} heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;~~

Z is chosen from ~~the group consisting of; C, N, or O;~~ CR_7 or N;

R_7 is H or C_1-C_5 alkyl;

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO_2H, CHO, NO_2, $-NH_2$, $-NH(C_1-C_4)$; $N(C_1-C_4)_2$, $-NH(C_6$aryl), $-N(C_6$ aryl$)_2$, $-NH(C_5-C_{10}$ heteroaryl), and $-N(C_5-C_{10}$ heteroaryl$)_2$; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:









wherein A is $-CN$ or $-NO_2$, and B is $-CN$, $-NO_2$ or $-SO_2CH_3$.

19. (Original) A compound according to claim 18, wherein R_1 or/and R_2 are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, $-(CH_2)_2SMe$, (R)-CH_2SCH_2Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.

20. (Previously Presented) A compound according to claim 18, wherein R_3 is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R_4.

21. (Previously Presented) A compound according to claim 18, wherein R_4 is H, methyl, or forms a keto group together with R_3.

22. (Currently Amended) A compound according to claim 18, wherein R_5 is NO_2, CN, or CH_2CN ~~or CO_2H~~.

23. (Previously Presented) A compound according to claim 18, wherein R_6 is Me or CF_3.

24. (Previously Presented) A compound according to claim 18, wherein R_7 is H or Me.

25. (Previously Presented) A compound according to claim 18, wherein R_8 is H or methyl.

26. (Cancelled)

27. (Currently Amended) A compound according to claim 18, wherein Y is ~~H,~~ -OH~~, -OMe, -N(CH$_2$CH$_3$)$_2$, piperidime, or 4-nitro-2-ylamino~~.

28. (Cancelled)

29. (Currently Amended) A compound according to claim 18, wherein the compound is chosen from the group consisting of:

2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-ol;

[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol

(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-propan-1-ol;

(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;

2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;

[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;

(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;

2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;

[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;

(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;

(S)-2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;

(DL)-3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

~~2-(2,3-Dimethyl-4-nitro-phenylamino)-2-mehtyl-propan-1-ol;~~

2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-ol;

(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;

4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((R)-1- Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((S)-1- Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;

6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;

and compounds having the formula:



in which R_9, R_6 and Z are as defined in the following table:

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH

R9	R6	Z		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	CH

R9	R6	Z		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		

R9	R6	Z
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH

R9	R6	Z
	CH_3	CH
	CH_3	CH

R9	R6	Z
	CH_3	CH
	CH_3	CH

~~4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzoic acid;~~

~~(6-Methyl-5-nitro-2-pyridin-2-ylamino)-butionic methyl ester;~~

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol

3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

~~2-(6-Methyl-5-nitro-pyridin-2-ylsulfanyl)-ethanol~~

~~[1-(4-Fluoro-3-methyl-phenylamino)-cyclopentyl]-methanol~~

~~1-[4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-phenyl]-ethanone~~

~~1-[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-ethanone~~

~~1-[4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-phenyl]-ethanone~~

[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol

2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol

4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol

4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile

[1-(4-Nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(4-Nitro-phenylamino)-pentan-1-ol

~~(S)-4-Methyl-2-(4-nitro-phenylamino)-pentan-1-ol~~

[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol

(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

30. (Previously Presented) A compound according to claim 18, wherein R_1 or R_2 is a C_6-C_{10} arythio comprising an aryl-substituted sulfur-containing C_1-C_{10} alkyl group.

31. (Previously Presented) A compound according to claim 18, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.

32. (New) A method of treating a disease caused by a disturbance in the activity of the androgen receptor comprising administering a compound comprising Formula I to a subject in need thereof, wherein Formula I is defined as:



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from hydrogen, halogen, C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} alkoxy, C_1-C_{10} alkenoxy, C_1-C_{10} alkynoxy, C_1-C_{10} alkylthio, C_1-C_{10} alkenylthio, C_1-C_{10} alkynylthio, C_6-C_{10} arylthio, C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C_1-C_{10} alkylarylsulphoxide, C_6-C_{10} aryl, or C_5-C_{20} heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R_1 and R_2 may together form a C_3-C_{10} cycloalkyl group;

R_3 and R_4 are the same or different and independently selected from hydrogen, halogen, C_1-C_{20} alkyl, C_3-C_7 cycloalkyl, C_2-C_4 alkenyl; C_2-C_4 alkynyl, C_1-C_4 alkoxy, C_1-C_4 alkenoxy, C_1-C_4 alkynoxy, C_1-C_4 alkylthio, C_1-C_4 alkenylthio, C_1-C_4 alkynylthio, C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C_1-C_{10} alkylarylsulphoxide, C_6-C_{15} aryl, C_5-C_{20} heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R_5 is chosen from nitro, cyano, -CH_2CN, -COMe, or -SO_2CH_3;

R_6 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CN, CO_2H, CHF_2, CH_2F or CF_3;

R_8 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CHF_2, CH_2F or CF_3;

X is -NH-;

Y is chosen from hydroxy, or -NH(C_1-C_{10} heteroaryl);

Z is chosen from CR_7 or N;

R_7 is H or C_1-C_5 alkyl;

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO_2H, CHO, NO_2, -NH_2, -NH(C_1-C_4); N(C_1-C_4)$_2$, -NH(C_6aryl), -N(C_6 aryl)$_2$, -NH(C_5-C_{10} heteroaryl), and –N(C_5-C_{10} heteroaryl)$_2$; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:









wherein A is –CN or $–NO_2$, and B is –CN, $–NO_2$ or $–SO_2CH_3$.

33. (New) A method according to claim 32, wherein R_1 or/and R_2 are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, $-(CH_2)_2SMe$, (R)-CH_2SCH_2Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.

34. (New) A method according to claim 32, wherein R_3 is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R_4.

35. (New) A method according to claim 32, wherein R_4 is H, methyl, or forms a keto group together with R_3.

36. (New) A method according to claim 32, wherein R_5 is NO_2, CN, or CH_2CN.

37. (New) A method according to claim 32, wherein R_6 is Me or CF_3.

38. (New) A method according to claim 32, wherein R_7 is H or Me.

39. (New) A method according to claim 32, wherein R_8 is H or methyl.

40. (New) A method according to claim 32, wherein Y is -OH.

41. (New) A method according to claim 32, wherein the compound is chosen from the group consisting of:
2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-ol;
[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-propan-1-ol;
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;
2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;
[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;
2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;
[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;

(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;

(S)-2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;

(DL)-3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-ol;

(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;

4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((R)-1- Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((S)-1- Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;

6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;

and compounds having the formula:



in which R_9, R_6 and Z are as defined in the following table:

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH

R9	R6	Z
	CF_3	CH
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	CH

R9	R6	Z
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH
	CH_3	CH

R9	R6	Z
	CH_3	CH
	CH_3	CH

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol

3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol

2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol

4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol

4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile

[1-(4-Nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(4-Nitro-phenylamino)-pentan-1-ol

[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol

(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

42. (New) A method according to claim 32, wherein R_1 or R_2 is a C_6-C_{10} arythio comprising an aryl-substituted sulfur-containing C_1-C_{10} alkyl group.

43. (New) A method according to claim 32, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.